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Highlights 
‐ Neutrophil extracellular traps (NETs) modify the structure and stability of fibrin. 
‐ NET content of thrombi varies at different locations (brain, heart, peripheral arteries). 
‐ DNA and histones in thrombi correlate with age and systemic inflammatory markers. 
‐ The amount of fibrin is similar at all examined arterial locations. 
‐ Thicker fibrin fibers are formed in coronaries than in brain and peripheral arteries. 
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Abstract 
Introduction-The ultrastructure and cellular composition of thrombi has a profound effect on 
the outcome of acute ischemic stroke (AIS), coronary (CAD) and peripheral artery disease 
(PAD). Activated neutrophils release a web-like structure composed mainly of DNA and 
citrullinated histones, called neutrophil extracellular traps (NET) that modify the stability and 
lysability of fibrin. Here, we investigated the NET-related structural features of thrombi 
retrieved from different arterial localizations and their interrelations with routinely available 
clinical data.  
Patients and methods-Thrombi extracted from AIS (n=78), CAD (n=66) or PAD (n=64) patients 
were processed for scanning electron microscopy, (immune)stained for fibrin, citrullinated 
histone H3 (cH3) and extracellular DNA. Fibrin fiber diameter, cellular components, DNA and 
cH3 were measured and analyzed in relation to clinical parameters.  
Results-DNA was least present in AIS thrombi showing a 2.5-fold lower DNA/fibrin ratio than 
PAD, whereas cH3 antigen was unvaryingly present at all locations. The NET content of 
thrombi correlated parabolically with systemic inflammatory markers and positively with 
patients’ age. The median platelet content was lower in PAD (2.2%) than in either AIS (3.9%) 
or CAD (3.1%) and thrombi from smokers contained less platelets than non-smokers. Fibrin 
fibers were significantly thicker in male patients with CAD (median fiber diameter 76.3 nm) 
compared to AIS (64.1 nm) or PAD (62.1 nm) and their diameter correlated parabolically with 
systemic inflammatory markers.  
Conclusions-The observed NET-related variations in thrombus structure shed light on novel 
determinants of thrombus stability that eventually affect both the spontaneous progress and 
therapeutic outcome of ischemic arterial diseases. 
 
Keywords: Fibrin, Myocardial infarction, Neutrophil Extracellular Traps, Peripheral Artery 
Disease, Stroke 
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Abbreviations:  
AIS     Acute ischemic stroke 
ASA     Acetylsalicylic acid 
CAD     Coronary artery disease 
cH3     Citrullinated histone H3 
CRP     C-reactive protein 
FD50 Median of fluorescent signal ratio of fibrin/extracellular 
DNA 
FH50 Median of fluorescent signal ratio of fibrin/citrullinated 
histone H3 
NET     Neutrophil extracellular trap 
PAD     Peripheral artery disease 
SEM     Scanning electron microscopy 
sF     Surface fibrin fiber occupancy 
sPlt     Surface platelet occupancy 
WBC     White blood cell 
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Introduction 
Cardiovascular disorders remain the leading cause of death worldwide, coronary artery 
disease (CAD) and acute ischemic stroke (AIS) representing the two medical conditions with 
the strongest impact on mortality and disability [1]. The prevalence of peripheral artery disease 
(PAD) has also increased in the past years [2], thus contributing to the growing disease burden 
of arterial thrombotic disorders.  
Intravascular clot formation has long been known to be linked to inflammation, but in 
the past decade a series of findings related to neutrophil extracellular traps (NETs) revealed 
new aspects of the role of inflammatory cells in hemostasis [3]. The scaffold of these web-like 
structures released by neutrophil granulocytes during a specific program of cell-death called 
NETosis [4] is composed mainly of DNA [5]. During the early phase of NETosis the arginine 
residues of histone proteins are being deiminated (citrullinated) by the enzyme peptidyl-
arginine-deiminase 4, thus cH3 is considered to be a specific marker of NETs [6]. Strong 
evidence supports the role of NETs in both deep venous [7-11] and arterial thrombi [12-14], 
and they are now regarded as an additional scaffold of thrombus formation tightly intertwined 
with the fibrin matrix. In a previous study, we demonstrated massive presence of extracellular 
DNA and histones in thrombi removed with surgery from patients with PAD [15] and recent 
studies showed the presence of NETs in ischemic stroke thrombi [16, 17]. 
Tissue damage in ischemic cardiovascular disease is often a consequence of 
embolization from unstable thrombi [18], whereas the clinical outcome of the interventional or 
lytic treatment in AIS, CAD and PAD is also affected by the structural phenotype of fibrin, the 
primary matrix of thrombi [19]. The structural features of fibrin are greatly modified in the 
presence of NET or extracellular matrix components and this modification determines the 
mechanical and lytic stability of thrombi [15, 20, 21]. These facts justify the growing interest 
in investigating thrombus composition [22, 23], but very few data are available concerning the 
fibrin structure in relation to the cellular and NET content of thrombi in the clinical setting of 
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AIS. In view of the expanding application of mechanical thrombectomy to treat large vessel 
occlusions causing AIS, elaborate characterization of NET components in the culprit clot 
composition could refine the need for new therapeutics targeting the NETs [17], whereas 
associations of clot composition and routinely available clinical data, as well as comparisons 
with thrombi from other therapeutic interventions (CAD, PAD) could help the identification of 
etiology- and localization-specific predictors for optimal post-interventional treatment to 
prevent re-occlusion. 
 
Patients and methods 
The detailed methods section is available as an Online Resource. 
Between 2014 and 2016, 208 consecutive patients (66 CAD, 64 PAD and 78 AIS) were 
prospectively enrolled (for patients’ characteristics see Online Resource Table I). Thrombi were 
collected during acute therapeutic catheter interventions in CAD, open surgery in PAD or via 
stent-retriever thrombectomy in AIS [24]. Informed written consent was obtained from all 
individual participants or their legal guardians. Our study was approved by the institutional and 
regional ethical board (Ref.#8/2014/18.09.2014). All procedures performed in studies involving 
human participants were in accordance with the ethical standards of the institutional and 
regional research committee and with the 1964 Helsinki declaration and its later amendments.  
Thrombus occupancy by cells and fibrin was determined from morphological 
examination of scanning electron microscopy (SEM) images. Thrombus composition was then 
expressed as percentage of regions occupied by each component out of the total area of the 
image. The morphometric analysis also included the manual measurement of 300 fibrin fiber 
diameters followed by evaluation of their distribution using scripts running under Image 
Processing Toolbox of Matlab R2015a (Mathworks, Natick, MA) as previously described [25-
27]. 
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Multiple (6 to 15, depending on the size of the thrombus sample) sections of each 
thrombus were fluorescently stained with the TOTO-3 nucleic acid dye for extracellular DNA 
and with indirect immunofluorescence staining for cH3 and fibrin. Confocal laser scanning 
microscopic images were taken and quantitatively analyzed based on the fibrin/DNA and 
fibrin/cH3 ratios determined from the image area covered by the respective fluorescent signal. 
For statistical evaluation each thrombus was characterized by a single parameter, the median of 
these area ratios in the separate sections (FD50 and FH50 for fibrin/DNA and fibrin/cH3, 
respectively).  
Regression analysis and statistical hypothesis testing were performed on an array of 
thrombus composition and routine clinical data of each patient. Previously described algorithms 
were used (Kuiper statistical test for equality of distribution [28], one-tail statistical test for 
median equality [25], linear regression models with response variable described as quadratic 
function of one or two explanatory variables [25]) with modifications detailed in the Online 
Resource. 
 
Results and Discussion 
Extracellular DNA and cH3 
Our previous in vitro [15] and a recent ex vivo [16] study provided evidence that NET 
components (DNA, histones) modify the structure of fibrin, increase its mechanical stability 
and render clots less sensitive to lysis with tissue-type plasminogen activator/plasminogen. In 
line with the recently reported findings in ischemic stroke thrombi [16, 17], our present work 
confirms the presence of NET components in AIS thrombi, but we also demonstrate that 
extracellular DNA content – the major meshwork-forming constituent of NETs – of AIS 
(median FD50 of 0.208) thrombi is similar to CAD and 2.5-fold lower than in PAD thrombi 
(median FD50 of 0.082, p=0.0013, Figure 1). Thus, compared to other artery locations, in AIS 
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the NET meshwork impedes the least the fibrinolytic therapeutic approach to restore the 
patency of occluded vessels, a fact that deserves attention when making therapeutic decisions 
in stroke. Diabetes also had a significant effect on the relative DNA content in PAD, the FD50 
ratio was 2-fold higher in diabetic than in non-diabetic patients (0.0654 vs. 0.1383, p=0.0131). 
 
Figure 1. Indirect immunofluorescent imaging and fibrin/DNA area ratio in arterial 
thrombi from coronary (CAD), peripheral artery disease (PAD), and acute ischemic 
stroke (AIS). Following interventional extraction of thrombi from coronary artery disease (A), 
peripheral artery disease (B) and acute ischemic stroke (C) patients, cryosections were prepared 
and treated with the fluorescent DNA dye TOTO-3, mouse anti-human fibrin and rabbit anti-
human cH3 antibodies followed by the respective species-specific fluorescent anti-IgG 
antibodies as described in Patients and methods. Images were taken with a confocal laser 
 9 
 
microscope (red, fibrin; green, cH3; blue, extracellular DNA). Based on the fluorescent signal 
the ratio of cross-section area occupied by fibrin and DNA was determined in 6-15 regions of 
each thrombus and the median values of these ratios for each thrombus (FD50) were evaluated 
(D). A lower value FD50 indicates a higher relative DNA content in clots. The columns and 
bars represent median and IQR values. The patient number in each group was nCAD=49, 
nPAD=57 and nAIS=64. p-values result from one-tailed hypothesis testing for medians 
(significant if p-value less than 0.05) using Bootstrap resampling of n’=10,000 for each 
statistical test. 
During the early phase of NETosis the arginine residues of histone proteins are being 
deiminated (citrullinated) by the enzyme peptydil-arginine-deiminase 4, thus cH3 is considered 
to be a specific marker of NETs [6]. This antigen was present in all clots (FH50, Figure I in the 
Online Resource) – in line with the recently reported findings in ischemic stroke thrombi [16]. 
No significant quantitative differences were observed between cH3 content at different vascular 
locations, which could be attributed to the role of citrullination limited to triggering NET 
formation and thus differences in the tiny quantities of citrullinated histones sufficient to initiate 
NETosis are not necessarily detectable after the completion of the process when we performed 
the observations. Because thrombin is able to degrade citrullinated histones [29], extracellular 
DNA appears to be a more stable marker of NETosis in thrombi. Such an interpretation of the 
FD50 and FH50 findings is in line with our results regarding the effects of oral anticoagulants, 
as the treatment with such drugs leads to a two-fold higher relative cH3 content in all thrombi 
(FH50 decreased from 1.431 to 0.665, p=0.0174). Because of the common use of statins in 
hypercholesterolemia, we evaluated the effects of these drugs on the NET markers in 
dyslipidemic patients: neither FH50, nor FD50 was changed by this cholesterol-lowering 
medication. 
 In view of the stabilizing impact of NETs on thrombi, an important observation from 
our work was that both the DNA and the cH3 content, as hallmarks of NETs, correlated 
positively with the patients’ age (except for cH3 in AIS). The regression models used to 
evaluate the associations are described in the Online Resource (Tables II-III). FD50 showed an 
inverse correlation in all main groups up to the age of 57 years (R2adj=0.30 and 0.33 in AIS and 
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PAD and a stronger association in CAD, R2adj=0.99) (Table 1, Figure III in the Online 
Resource). In AIS no further associations with FD50 were revealed, but in CAD an inverse 
correlation was found between FD50 and fibrinogen level, and a parabolic association between 
FD50 and WBC count with a minimum at 11×103/µL (Figure IVB in the Online Resource). A 
parabolic regression model described the dependence of FD50 on C-reactive protein (CRP) in 
the range of 0-7.2 mg/L in PAD thrombi (Figure IVC in the Online Resource). Absolute 
neutrophil count showed similar, parabolic interrelation with FH50, with a minimum at about 
5 to 8×103/µL (Figure VI and Table II in the Online Resource). These data suggest the local 
inflammatory process accompanied by NET release in thrombi is associated with mild to 
moderate increase in the systemic signs of inflammation (WBC, CRP), whereas their extremely 
high systemic levels are probably related to additional loci, distinct from the thrombi.  
  FD50 FH50 
 R2adj n pANOVA R2adj n pANOVA 
All patients       
 Neutrophil count - - - 0.38 28 1.22×10-3 
Coronary artery disease     
Age at intervention 0.99 21 2.98×10-11 0.71 21 6.09×10-5 
WBC  0.48 35 1.50×10-5 - - - 
Neutrophil count 0.89 13 1.81×10-4 - - - 
Fibrinogen level 0.58 22 6.19×10-4 - - - 
Peripheral artery disease    
Age at operation 0.33 18 3.68×10-2 0.39 41 4.33×10-5 
CRP 0.75 12 6.31×10-3 - - - 
Acute ischemic stroke    
Age at intervention 0.3 18 5.71x10-2 - - - 
Neutrophil count - - - 0.63 23 3.36×10-5 
Table 1. Strength of association between median fibrin/DNA ratio (FD50), median 
fibrin/cH3 ratio (FH50) and patient age or inflammatory laboratory markers. The 
regression models and their coefficients for each dependence are presented as an Online 
Supplement (Tables II&III). WBC=white blood cell count, CRP=C-reactive protein, n=sample 
size, R2adj=adjusted coefficient of determination, pANOVA=p-value of the analysis of variance 
(significant if p-value less than 0.05), (-), no considerable dependence (R2adj<0.3), n=sample 
size constrained to variable range for which the dependence is valid (defined in Table II). 
 
In AIS no significant association was found between FH50 and age at intervention, 
whereas in the CAD group FH50 showed an inverse correlation with age (R2adj=0.71). The same 
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association pattern could be observed in PAD between age 50 to 80, and a positive correlation 
above 80 years (n=11, R2adj=0.52, pANOVA=1.7×10-2). Because histones are known to confer 
mechanical and lytic resistance to fibrin [15], this data can be interpreted as an age-dependent 
clot-stabilizing effect, which suggests an improved response to lytic treatment in younger 
patients, as well as that stabilization of the structure in older patients could favor the success of 
mechanical intervention. In addition, in PAD the strength of association between the NET 
content of thrombi and patients’ age was increased by atherosclerotic etiology or systemic 
indicators of inflammation (CRP, leukocytosis, plasma fibrinogen) (Table II).  
The age trend in FH50 of AIS patients was reinforced by malignant co-morbidities, 
known to exert an independent NET-promoting effect [30], to an R2adj value of 0.90 which 
points to an increased lytic resistance in this subgroup of patients (Table II). Generally 
(evaluating all main groups together) the interrelation of the local NET-marker FH50 and the 
systemic inflammatory indicators followed a rather complex trend in thrombi removed from 
patients with malignancy (Figure 2). Although FH50 correlated positively with WBC count at 
fibrinogen levels less than 4 g/l, the correlation was inverted at higher fibrinogen concentrations 
(n=20, R2adj=0.65, pANOVA=1.9×10-4). 
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Figure 2. The joint impact of fibrinogen and white blood cell count on the ratio of 
fibrin/cH3 in thrombi extracted from patients with malignancy. The regression model and 
its coefficients are presented as an Online Supplement (Table III). Regression surface is shown 
for data points (o) after outlier (x) rejection. FH50=The median of fluorescent signal ratio of 
fibrin/cH3, WBC=White blood cell count. 
 
Platelets in thrombi 
Because of the known direct [31-35] and indirect (through von Willebrand factor [36]) 
NET interactions with platelets and the role of platelets in fibrin formation [37], it was of 
interest to look at platelet content of the clots. Although in this study we did not observed any 
associations between measured platelet occupancy and NET components, the SEM analysis of 
cellular components of thrombi retrieved from AIS, CAD and PAD patients revealed a marked 
difference in their platelet content (sPlt, Figure 3). AIS thrombi showed 1.8-fold higher median 
platelet occupancy than PAD thrombi (sPlt 3.9 vs. 2.2%, p<0.001), whereas sPlt difference 
from CAD thrombi was observed only in male patients (4.9% in AIS vs. 2.8% in CAD, 
p=0.0032). These several-fold differences in sPlt can lead to major downstream alterations 
through the signal amplification of the coagulation cascade as platelets usually initiate clotting 
in arteries. Our sPlt results in CAD were similar to those reported before by others [38], 
however concerning AIS other studies found higher platelet content in thrombi [39, 40].  The 
inconsistency of these data could be a result of many factors: group heterogeneity, the smaller 
sample size in the earlier AIS studies, variations in the rheological conditions of the culprit sites 
of emboli causing stroke. 
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Figure 3. Platelet content of arterial thrombi from from coronary (CAD), peripheral 
artery disease (PAD), and acute ischemic stroke (AIS). The area of SEM images occupied 
by platelets or platelet conglomerates (indicated by arrows) was determined as percentage of 
the total thrombus area (sPlt) as described in Patients and methods (A). The number of 
observations (evaluated thrombus images, #O) were #OCAD=301 (from n=62 patients), 
#OPAD=298 (n=61) and #OAIS=376 (n=77). B: The columns and bars represent median and IQR 
values. p-values result from one-tailed hypothesis testing for medians (significant if p-value 
less than 0.05) using Bootstrap resampling of n’=10,000 for each statistical test. 
 
Several factors could be identified as modulators of platelet content (Table 2). In AIS 
with atherosclerotic etiology the median of the sPlt values (2.7%) was 2-fold lower than in the 
rest of the AIS cases (5.4%), but no such etiology-related difference was seen in PAD thrombi. 
The presence of a malignant neoplasm was associated with a decreased median sPlt (1.9%) 
compared to patients with no malignant comorbidity (4.4%) only in AIS thrombi, but not in 
CAD and PAD. In thrombi removed from diabetic patients we measured lower sPlt values 
(2.1% compared to 3.2% in non-diabetic patients, p<0.001). Renal insufficiency had no 
significant effects on the investigated structural parameters. Smoking is a recognized risk factor 
in ischemic cardiovascular diseases, but a recent study showed that in ST-elevation myocardial 
infarction the platelet content of thrombi was not altered by smoking [41]. In the current study 
we observed that in all main groups, the size of which allowed for statistical evaluation, the 
thrombus occupancy by platelets was more than two-fold lower in active smokers compared to 
non-smokers, median sPlt 3.6% vs. 1.6% in CAD and 3.2% vs. 1.6% in PAD (there were only 
2 documented non-smokers in the AIS group, thus no statistical evaluation could be done). This 
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surprising finding could be attributed to a phenomenon observed in studies designed to evaluate 
platelet responsiveness to clopidogrel. Whole blood aggregation-based assays indicated 
improved drug-response in smokers compared to non-smokers (“smokers’ paradox”). However, 
a careful analysis of the laboratory data revealed that this apparent improvement in the 
inhibition of platelet reactivity in whole blood aggregation is related to an off-drug effect of 
hematocrit [42, 43]. Smokers are known to have higher hemoglobin levels [44] and in our study 
a similar difference was observed with blood hemoglobin of 8.6 mmol/L in smokers (n=74) 
versus 7.9 mmol/L in non-smokers (n=61, p=0.0124), which could contribute to the observed 
difference in the platelet content of thrombi. Interestingly, blood platelet content was not 
associated with sPlt. 
Main group 
Comorbidity/risk factor 
sPlt % 
medno 
sPlt % 
medyes pmed pdistr #Ono #Oyes 
All patients       
Diabetes 3.2 2.1 <0.001 1.000 724 (148) 248 (50)
CAD       
Smoking 3.6 1.6 0.011 0.669 166 (33) 99 (21) 
Malignancy 2.5 3.9 0.139 0.047 244 (50) 57 (12) 
PAD       
Atherosclerosis 3.0 2.0 0.097 0.728 60 (13) 233 (47)
Smoking 3.2 1.6 0.004 0.935 115 (24) 178 (36)
Malignancy 2.0 3.4 0.059 0.207 258 (53) 35 (7) 
AIS       
Atherosclerosis 5.4 2.7 <0.001 0.072 175 (37) 196 (39)
Smoking 8.0 2.4 0.164 0.771 11 (2) 67 (13) 
Malignancy 4.4 1.9 <0.001 1.000 308 (64) 63 (12) 
Diabetes 4.2 2.5 0.001 1.000 293 (61) 78 (15) 
Table 2. Platelet content (sPlt) of thrombi from coronary (CAD), cerebral (AIS) and 
peripheral (PAD) arteries in the presence and absence of comorbidities and risk factors. 
The area occupied by platelets on SEM images of thrombi was determined as percentage of the 
total thrombus area, as described for Fig. 3. #O=number of observations (evaluated thrombus 
images); the numbers in parentheses after the #O indicate the numbers of patients included in 
the respective groups; med=median; no/yes in subscript refers to the presence of the respective 
comorbidity/risk factor; pmed=p-value resulting from one-tailed hypothesis testing for medians 
(significant if p-value less than 0.05); pdistr=p-value from Kuiper-test for distributions 
performed with Bootstrap resampling of n=10,000 for each statistical test. 
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Fibrin content and fibrin fiber thickness 
Because of the known effects of NET components on purified fibrin structure [15], in 
the present study we investigated the alterations in fibrin content and fiber thickness in thrombi. 
Although the fibrin fiber occupancy (sF) was statistically higher in PAD thrombi (98.1±5.6%) 
compared to AIS (97.1±7.93%, p=0.043) or CAD (96.8±8.1%, p=0.0081) groups, these 
differences were not considerable in magnitude and thus fibrin content could be used as a 
reference value for the content of NET constituents (justifying the interpretation of the FD50 
and FH50 ratio values as measures of DNA and cH3 content of thrombi).  
Fibrin fiber thickness has a direct effect on the viscoelastic properties of the clots and 
their mechanical stability [45]. The median of fibrin fiber diameter measured in this study was 
significantly higher in CAD thrombi compared to AIS or PAD samples (Figure 4). These 
tendencies in the fiber size of the three main groups were due to the structural pattern of fibrin 
in male patients (median fiber diameter in CAD: 76.3 nm [67.2-90.8, n=41; AIS: 64.1 nm [58.6-
85.3] n=46, p=0.0093 compared to CAD; PAD: 62.1 nm [57.4-75.2], n=34, p=0.0002 compared 
to CAD), whereas fiber diameter did not differ in females from these groups. Because the 
mechanical stability of thicker fibrin fibers is higher [45], this data indicates that thrombi of 
male CAD are the most stable. Furthermore, chronic acetylsalicylic acid (ASA) treatment prior 
to the acute ischemic event was associated with an increased fiber diameter only in males (No 
ASA: 64.4 nm [58.6-78.4] n=45; ASA: 70.9 nm [61.9-88.8] n=68, p=0.022). ASA had no other 
significant effects on the measured structural parameters. Regarding comorbidities, 
accompanying malignant neoplasms reduced fibrin fiber thickness only in PAD (No malignant 
comorbidity: 64.3 nm [59.2-73.8] n=53 vs. malignant comorbidity: 57.9 nm [54.1-58.7], n=7, 
p=0.018), but not in AIS and CAD.   
The alterations in fibrin structure cannot be attributed to the effect of NETs, because 
PAD thrombi showed the highest relative DNA and cH3 content and the thinnest fibers, 
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whereas in purified fibrin clots DNA and histones increase the fiber diameter [15]. This 
discrepancy could be explained at least in part by differences in pre-procedural medication. 
While all CAD patients received chronic ASA prophylaxis, only a quarter of the AIS and half 
of the PAD patients were treated with ASA prior the acute intervention. ASA is known to have 
platelet-independent effects, such as fibrin acetylation, which leads to thicker fibers [46, 47]. 
Clinical trials demonstrate sex differences in response to ASA treatment [48], which is in 
agreement with our data showing that ASA treatment results in thicker fibrin fibers only in male 
patients. 
 
Figure 4. Fibrin fiber diameter in thrombi removed from different localizations. Manual 
measurement of 300 fibrin fiber diameters was performed on 5 SEM images of each thrombus 
followed by evaluation of their distribution. A: Coronary artery disease (CAD), B: Peripheral 
artery disease (PAD), C: Acute ischemic stroke (AIS). The graphs show the probability density 
function (PDF) of the empiric distribution (black histogram) and the fitted theoretical lognormal 
distribution (gray curve). Median values are indicated by vertical lines. The number of thrombi 
in each group was nCAD=62, nPAD=61, nAIS=77. Both the PAD (p=0.0026) and the AIS group 
(p=0.0132) had a significantly lower median fibrin fiber diameter, as compared to CAD samples 
according to one-tailed hypothesis test (significant if p-value less than 0.05) using Bootstrap 
resampling of n’=10,000. 
Out of the three main groups only in AIS thrombi a parabolic dependence of fibrin fiber 
median on CRP was found with a minimum at about 5 mg/L CRP (n=16, R2adj=0.48, 
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pANOVA=1.1×10-6). CAD thrombi showed a similar correlation between the median diameter of 
fibrin fibers in thrombi and another acute phase protein, the plasma fibrinogen with a minimum 
at 4.0 g/L (n=35, R2adj=0.35, pANOVA=1.9×10-4, Figure II and Table II in the Online Resource). 
The previously reported data on the association of fibrin structure and CRP are inconsistent and 
controversial with studies variably showing that: 1) CRP-treated fibrin clots had thicker fibrin 
fibers [49]; 2) a lower CRP (<2 mg/L) was associated with greater fibrin fiber diameters 
compared to CRP>5 mg/L in thrombi removed from CAD [50]. In our study fibrin fiber 
diameters did not differ significantly in CAD patients with low CRP (<5 mg/L), compared to 
those with higher values (71.88 nm [63.34-86.24] n=43 vs. 72.26 nm [61.12-98.48], n=18, 
p=0.4825) probably due to the dominant ASA effect discussed above. Plasma fibrinogen level 
also showed a correlation with symptom-to-intervention time (Figure VII and Table II in the 
Online Resource). A strong parabolic regression (n=35, R2adj=0.34, pANOVA=8.3×10-8) was 
observed in thrombi retrieved in less than 24 hours after the onset of symptoms, with the 
minimum value at about 6 hours. CRP showed no significant association with time. Similarly, 
we did not identify any significant associations between symptom-to-intervention time and 
platelet occupancy, fiber diameter, FD50 or FH50. 
 
Study limitations 
 Our study has several limitations arising both from the extraction and the processing of 
thrombi. We were able to study only thrombi that had been successfully retrieved. Moreover, 
even removed thrombi could have been partially fragmented, without the embolic debris, which 
might not be completely representative of the whole in situ clot structure. The extraction of 
clots was performed using different techniques at the different locations (heart, brain, peripheral 
artery), which in the case of thrombus aspiration may lead to the distortion of structure. Another 
source of error is the heterogeneity of thrombi, especially if we consider the old age of some 
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peripheral clots. It is highly probable that these samples contain older, more organized parts as 
well as fresh sections only recently formed on the surface with distinct structural differences. 
Finally, there are numerous factors that can affect thrombus structure, and thus it is hard to 
evaluate the effects of only one isolated determinant. These limitations were at least partially 
overcome by the number of processed samples, by imaging multiple sections from different 
parts of the thrombi, and using a robust statistical evaluation, including the homogeneity 
verification of the compared groups. 
 
Conclusion 
This study provides comparative data on the NET content and related platelet occupancy 
and fibrin structure of thrombi extracted from patients with acute ischemic stroke, myocardial 
infarction and peripheral artery disease. These results further our understanding of the structural 
determinants of the mechanical and lytic stability of thrombi and thus they may contribute to 
refine the strategies for interventional or enzymatic treatment of acute thrombotic episodes, as 
well as to provide clues for targeted secondary prevention. 
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Detailed methods 
Patient characteristics 
Between 2014 and 2016, 208 consecutive patients (66 coronary artery disease, CAD patients; 64 peripheral artery disease, PAD 
patients and 78 acute ischemic stroke, AIS patients) were prospectively enrolled. Clinical characteristics and basic laboratory findings 
of the patient cohort are summarized in supplementary Table I. Atherosclerosis was diagnosed if atherosclerotic plaques were visible 
during the procedure or via carotid ultrasound (B mode). The patients were considered dyslipidemic if they had elevated fasting blood 
cholesterol or triglyceride levels, or were on lipid lowering therapy. Thrombophilia was determined from patient history. 
Thrombus collection 
In the case of CAD and PAD patients thrombi were collected during acute therapeutic catheter interventions and operations, as 
previously described [1]. In AIS, thrombi were removed via stent-retriever thrombectomy from acutely occluded large vessels of the 
circle of Willis. All patients with a definite diagnosis of AIS eligible for mechanical thrombectomy were included during the study 
period providing that a clot was successfully removed. Prior to mechanical thrombectomy recombinant tissue-type plasminogen 
activator was administered to patients who were eligible for intravenous thrombolysis. The study was approved by the institutional and 
regional ethical board (Ref.#8/2014/18.09.2014) and informed written consent was obtained from all participants or their legal 
guardians. The research also conforms to the principles outlined in the Declaration of Helsinki. 
Scanning Electron Microscope (SEM) imaging 
Samples were fixed and processed immediately after extraction according to a previously published method [2], which was 
followed by taking randomly selected images from separate parts of thrombi to control for composition heterogeneity. Altogether 10 
images were taken of each thrombus with SEM EVO40 (Carl Zeiss GmbH, Oberkochen, Germany), using two different magnifications 
(5000x, 20000x). Surface occupancy of cellular components and fibrin network was determined in typically 5 images (exceptionally 4) 
at the lower magnification after dividing the images to 864 equal sized square regions of interest using Photoshop 7.0.1 CE (Adobe, 
San José, CA, USA) and based on morphological characteristics each region was classified as occupied by fibrin, platelets, other blood 
cells or their combinations. Thrombus composition was then calculated as percentage of regions occupied by each component out of 
the total area of the image as previously described [3]. The morphometric analysis also included the manual measurement of 300 fibrin 
fiber diameters followed by evaluation of their distribution using scripts running under Image Processing Toolbox of MatLab R2015a 
(Mathworks, Natick, MA) as previously described [1, 2, 4]. 
Immunofluorescent imaging 
Thrombus samples were placed in isopentane immediately after intervention and stored at -80°C until further processing. 
Cryosections of 6 µm thickness were made from 6 to 15 different areas of the thrombi, depending on thrombus size. Extracellular 
 
 
DNA, citrullinated histone H3 (cH3) and fibrin network were identified using dimeric cyanine nucleic acid dye TOTO-3 for DNA (T-
3604, Life Technologies, Budapest, Hungary), mouse anti-human fibrin (ADI311, Sekisui, Pfungstadt, Germany) and rabbit anti-
human citrullinated histone H3 monoclonal antibodies (ab5103, Abcam, Cambridge, UK). To visualize fibrin and cH3 Alexa Fluor 488 
goat anti-rabbit IgG (A11008, Life Technologies, Budapest, Hungary) and Alexa Fluor 546 goat anti-mouse IgG (A11003, Life 
Technologies, Budapest, Hungary) antibodies were used. Fifteen images were taken from each thrombus using confocal laser scanning 
microscopy (Zeiss LSM 710, EC Plan-Neofluar 20x/0.50 M27 objective, Carl Zeiss, Jena, Germany) with the following 
excitation/emission wavelengths: fibrin: 543/589, cH3: 488/516 and DNA: 633/670. To quantify the area of different fluorescent 
signals Image J software (NIH, Bethesda, MD, USA) was used as previously described [1], median values of fibrin/DNA (FD50) and 
fibrin/citrullinated histone H3 ratio (FH50) distribution were determined.  
Statistical analysis 
Each patient was characterized by an array of routine clinical data, immunofluorescent data, fiber diameter and surface 
occupancy data from tj number of SEM images. The data were analyzed using regression analysis and/or hypothesis testing for 
identifying characteristics, dependences and influences between the different features of the patients. If the analyzed dependencies did 
not include the occupancy data, the sample sets are crisp, because each patient’s data forms one observation in the sample. However, if 
occupancy data were analyzed, the sections of a thrombus could not be treated as separate observations, because the intra-individual 
heterogeneity would have been neglected and the patients with larger sets of SEM data would be ascribed a higher weight in the 
conclusion derived. That is why, the sets of occupancy data were treated as fuzzy samples. The degree of membership to the general 
population of any observation of patient number j in such a fuzzy sample was assumed to be 1/tj. The so formed fuzzy sample 
accounted for inter-individual heterogeneity in thrombus occupancy, because each patient would influence the conclusions equally. 
A Kuiper statistical test for equality of distribution [5] and a one-tail statistical test for median equality [1] were used to identify 
differences in the characteristics of two one-dimensional continuous populations. Each of the populations was represented by 
independent and identically distributed samples of observations which could be either crisp or fuzzy.  In  order to achieve highly 
confident estimates of the statistical significance of differences of data showing large dispersions within samples of a relatively small 
size, bootstrap procedures that do not use any parametric assumptions were implemented with 10,000 pseudo-realities [6] and equal 
size generation over empirical cumulative distribution function as previously described [7]. Thus, we achieve a higher discriminative 
power than the conventional statistics in high-dispersion samples (reducing the p-values for real differences and increasing the p-
values for no differences independently of the pattern of data distribution). 
The linear regression models with response variable described as quadratic function of one or two explanatory variables were 
built using previously described algorithms [1] with modifications. The singular value decomposition of the design matrix and the 
outlier detection algorithm using multiple testing procedures were the same. The major modification was that weighted least square 
 
 
estimator was used as a coefficient estimator with weights equal to the membership degrees of the observations in the fuzzy sample. 
The false discovery rate was assumed 10% [8]. The critical p-value of 0.05 was used for all other statistical tests. 
 
Supplemental Tables, Figures and Figure Legends 
 
In this section we provide additional information for a more detailed and complete view of the results reported in the main text of the 
article. Clinical characteristics and basic laboratory findings of the patient cohort are summarized in the supplementary Table I. Figure 
I represents the relative citrullinated histone H3 content of peripheral, coronary artery disease and acute ischemic stroke as FH50. 
Table II shows the associations between fibrin fiber median, the median values of fluorescent fibrin/DNA (FD50), fibrin/citrullinated 
histone H3 ratio (FH50) and clinical data; as well as constraints that strengthen the regressions. For the visual presentation of the 
correlations seen in Table II, each regression is plotted on Figures II-VII. The 3D regression model of Figure 5 in the main text and its 
coefficients are reported in Table III. As supplementary data we also present the joint impact of fibrinogen level and patients’ age on 
the ratio of fluorescent fibrin/extracellular DNA in Figure VIII. The model, and the coefficients of this regression are also reported in 
Table III. 
  
 
 
Table I. Patient characteristics. Values are provided as mean ± SD or percentages, median values with lower and upper quartiles in 
brackets followed in parenthesis by the number of subjects included in the analysis. WBC=white blood cell count, Plt=platelet count, 
CRP=C-reactive protein, Hgb=hemoglobin,  ASA=acetylsalicylic acid, rtPA=recombinant tissue-type plasminogen activator. 
  CAD (66) PAD (64) AIS (78) All (208) 
Patient characteristics 
Male 68.2% (45/66) 56.3% (36/64) 61.5% (48/78) 62% (129/208) 
Patients’ age 63±14.9 (66) 68.7±10.8 (64) 60±10.5 (78) 63.6±12.6 (208) 
Laboratory findings 
WBC (103/µL) 12.4±4.9 (66) 10.1±3.5 (62) 10.6±4.1 (78) 11±4.3 (206) 
Plt (103 /µL) 233±78 (66) 222±87 (62) 213±60 (78) 222±75 (206) 
CRP (mg/L) 12.9±25.6 (65) 29.2±49.5 (33) 12±22.7 (62) 15.9±31.6 (160) 
Hgb (mmol/L) 8.3±1.3 (66) 7.8±1.8 (62) 8.3±1.3 (78) 8.1±1.5 (206) 
Fibrinogen (g/L) 3.7±1.1 (49) 4.1±1.2 (36) 2.4±1.3 (29) 3.5±1.4 (114) 
Leukocytosis (WBC>104 /µL) 63.6% (42/66) 40.3% (25/62) 48.7% (38/78) 51% (105/206) 
Elevated CRP (CRP>10 mg/L) 29.2% (19/65) 51.5% (17/33) 25.8% (16/62) 32.5% (52/160) 
Elevated fibrinogen (Fibrinogen>4 g/L) 36.7% (18/49) 52.8% (19/36) 6.9% (2/29) 34.2 (39/114) 
Etiology 
Thrombophilia 0% (0/66) 0% (0/17) 5.2% (4/77) 2.5% (4/159) 
Cardiac embolization 0% (0/66) 11.8% (2/17) 49.4% (38/77) 25.2% (40/159) 
Atherosclerosis 100% (66/66) 70.6% (12/17) 26% (20/77) 61% (97/159) 
Dissection 0% (0/66) 0% (0/17) 3.9% (3/77) 1.9% (3/159) 
Cryptogenic 0% (0/66) 17.6% (3/17) 15.6% (12/77) 9.4% (15/159) 
Data of thrombi 
Vessel diameter (mm) 3.3±0.6 (66) 10.5±15.6 (63) 2.5±0.7 (78) 5.2±9.3 (207) 
Symptom-to-intervention time (h) 3 [2-8.75] (58) 24 [12-48] (57) 5.3 [4.4-6.5] (77) 6 [4-12] (192) 
Medication prior to intervention 
ASA 100% (62/62) 41.9% (26/62) 24.7% (18/73) 53.8% (106/197) 
Clopidogrel 100% (62/62) 22.6% (14/62) 12.3% (9/73) 43.1% (85/197) 
Oral anticoagulant - 6.7% (1/15) 19.5% (15/77) - 
rtPA - - 51.3% (40/78) - 
Heparin 100% (66/66) 100% (64/64) 100% (78/78) 100% (208/208) 
Statin 13% (8/64) 42% (22/52) 25% (16/63)  (46/179) 
Comorbidities and risk factors 
Atherosclerosis 100% (66/66) 79.4% (50/63) 50.6% (39/77) 75.2% (155/206) 
 
 
Diabetes 25.8% (17/66) 31.7% (20/63) 20.8% (16/77) 25.7% (53/206) 
Hypertonia 69.7% (46/66) 79.4% (50/63) 79.2% (61/77) 76.2% (157/206) 
Hyperlipidaemia 50% (33/66) 55.6% (35/63) 35.1% (27/77) 46.1% (95/206) 
Uremia 18.2% (12/66) 9.5% (6/63) 0% (0/78) 8.7% (18/207) 
Thrombophilia 3% (2/66) 1.6% (1/63) 2.6% (2/78) 2.4% (5/207) 
Tumor 18.2% (12/66) 11.1% (7/63) 15.6% (12/77) 15% (31/206) 
Smoking 
Never 54% (34/63) 41.3% (26/63) 12.5% (2/16) 43.7% (62/142) 
Former 7.9% (5/63) 0% (0/63) 6.3% (1/16) 4.2% (6/142) 
Currently smoking 38.1% (24/63) 58.7% (37/63) 81.3% (13/16) 52.1% (74/142) 
 
 
 
 
  
Figure I. Fibrin/citrullinated histone H3 (cH3) area ratio in arterial thrombi from different localizations. Based on the 
fluorescent signal (Fig. 1 in the main text) the ratio of cross-section area occupied by fibrin and cH3 was determined in 6-15 regions of 
each thrombus and the median values of these ratios for each thrombus (FH50) were evaluated. A lower value FH50 indicates a higher 
relative cH3 content in clots. The columns and bars represent median and IQR values. The number of patients in each group was 
 
 
nCAD=49, nPAD=57 and nAIS=64. CAD=coronary artery disease, PAD=peripheral artery disease, AIS=acute ischemic stroke. p-values 
result from one-tailed hypothesis testing for medians (significant if p-value less than 0.05) using Bootstrap resampling of n’=10,000 
for each statistical test. 
Table II. Relationship between fibrin fiber median, fibrin/extracellular DNA ratio (FD50), fibrin/citrullinated histone H3 ratio 
(FH50) and age of patients or inflammatory laboratory markers. CAD=coronary artery disease, PAD=peripheral artery disease, 
AIS=acute ischemic stroke; ASA= acetylsalicylic acid; x, y=independent variables for 2D regression model; n=sample size, 
R2adj=adjusted coefficient of determination, pANOVA=p-value of the analysis of variance (significant if p-value less than 0.05), A0, A1, 
A2: coefficients of the 2D regression model; equation for 2D regression model: y=A0+A1*x+A2*x2+e. Only clinical constraints that 
increase the strength of association (R2adj) of the y,x pairs are presented with the respective modified R2adj values. 
 
Main 
group y x 
Limitation 
of variable 
x 
n R2adj pANOVA A0 A1 A2 Constraints R2adj
All 
Fibrinogen 
level (g/L) 
Symptom-to-
intervention 
time (h) 
<24 35 0.34 8.3x10-8 3.9 -4.0x10-1 3.0x10-2 
Male 0.53
ASA 0.35
Atherosclerotic 0.42
Smoker 0.47
<6.0 20 0.45 9.1x10-6 2.2 1.06 -0.2095 Male 0.55
FH50 Neutrophil count (103/µL) <7.0 28 0.38 1.2x10-3 101.8 -4.0x10-1 3.8x10-4 
Female 0.86
Hypertensive 0.50
CAD 
Fibrin fiber 
median 
Fibrinogen 
level (g/L) >2.0  35 0.35 1.9x10-4 1.9x10-1 -5.9x10-2 7.3x10-3 
ASA 0.45
Clopidogrel 0.45
Hypertensive 0.77
Smoker 0.36
FD50 
Age at 
intervention 
(years) 
<59  21 0.99 3.0x10-11 5.4 -2.0x10-1 1.8x10-3 - - 
Fibrinogen 
level (g/L) >3.1  22 0.58 6.2x10-4 2.6 -1.00 9.5x10-2 Male 0.69
WBC count <16.9  35 0.48 1.5x10-5 2.1 -3.6x10-1 1.7x10-2 Female 0.74
 
 
(103/µL) ASA 0.54
Clopidogrel 0.54
Elevated 
fibrinogen 0.71
FH50 
Age at 
intervention 
(years) 
<59  21 0.71 6.1x10-5 87.8 -3.1 2.8x10-2 
Male 0.86
ASA 0.79
PAD 
FD50 
Age at 
operation 
(years) 
<66  18 0.33 3.7x10-2 10.3 -3.8x10-1 3.5x10-3 
Atherosclerotic 0.47
Hypertensive 0.39
Smoker 0.41
CRP (mg/L) <7.2  12 0.75 6.3x10-3 3.2x10-1 -1.5x10-1 1.71x10-2 - - 
FH50 
Age at 
operation 
(years) 
50-80  41 0.39 4.3x10-5 15.0 -1.9x10-1 - 
Female 0.98
ASA 0.87
Clopidogrel 0.47
Diabetic 0.90
Hypertensive 0.47
Elevated CRP 0.90
>80  11 0.52 1.7x10-2 - -1.7x10-1 2.1x10-3 Hypertensive 0.61
AIS 
Fibrin fiber 
median CRP (mg/L) <24  16 0.48 1.1x10-6 7.2x10-2 -3.7x10-3 3.4x10-4 
Male 0.56
Leukocytosis 0.82
FD50 
Age at 
intervention 
(years) 
<57  18 0.30 5.7x10-2 3.9 -1.7x10-1 1.9x10-3 Male 0.81
FH50 
Age at 
intervention 
(years) 
- 64 0.02 - - - 3.8x10-3 Tumor 0.90
Neutrophil 
count (103/µL) <7.0 23 0.63 3.4x10-5 145.2 -5.6x10-1 5.3x10-4 Hypertensive 0.81
 
 
 
 
 
Figure II. Associations between fibrin fiber median and fibrinogen in coronary artery disease (A), C-reactive protein (B) in 
acute ischemic stroke. Fibrin fiber median determined by morphometric analysis of scanning electron micrographs shown as a 
function of blood fibrinogen level for coronary artery disease (A) and C-reactive protein (CRP) in acute ischemic stroke (B) thrombi. 
Regression curve (solid line) according to the model equation in Table II with 95% confidence intervals (dashed lines) is shown for 
data points (o) after outlier (x) rejection. 
 
 
 
 
 
Figure III. Associations between the median of fibrin/extracellular DNA ratios (FD50) and the age of patients in coronary 
artery disease (A), peripheral artery disease (B) and acute ischemic stroke (C). Regression curve (solid line) according to the 
model equation in Table II with 95% confidence intervals (dashed lines) is shown for data points (o) after outlier (x) rejection (2 
outliers are not shown because they are out of the chosen ordinate scale). 
 
 
Figure IV. Associations between the median of fibrin/extracellular DNA ratio (FD50) and blood fibrinogen level (A), white 
blood cell (WBC) count (B) in coronary artery disease, and C-reactive protein (CRP) in peripheral artery disease (C). 
Regression curve (solid line) with 95% confidence intervals (dashed lines) is shown for data points (o) after outlier (x) rejection (2 
outliers are not shown because they are out of the chosen ordinate scale). 
 
 
 
 
Figure V. Associations between the median of fibrin/citrullinated histone H3 ratio (FH50) and the age of patients in coronary 
artery disease (A), and peripheral artery disease (B, C). Regression curve (solid line) with 95% confidence intervals (dashed lines) 
is shown for data points (o) after outlier (x) rejection (2 outliers are not shown because they are out of the chosen ordinate scale). 
 
 
 
Figure VI. Associations between absolute neutrophil count (Neu) and fibrin/citrullinated histone H3 ratio (FH50) in acute 
ischemic stroke (A) and in all groups (B). Regression curve (solid line) with 95% confidence intervals (dashed lines) is shown for 
data points (o) after outlier (x) rejection (2 outliers are not shown because they are out of the chosen ordinate scale). 
 
 
Figure VII. Associations between symptom to intervention time and plasma fibrinogen concentration including all groups. 
Symptom to intervention time less, than 6 hours (A), or 24 hours (B). Regression curve (solid line) with 95% confidence intervals 
(dashed lines) is shown for data points (o) after outlier (x) rejection. 
 
Table III. Relationship between fibrin/extracellular DNA ratio (FD50), fibrin/citrullinated histone H3 ratio (FH50) and 
inflammatory laboratory markers, age of patients. WBC=White blood cell count; y, x1,x2=independent variables for 3D regression 
model; n=sample size, R2adj=adjusted coefficient of determination, pANOVA=p-value of the analysis of variance (significant if p-value 
less than 0.05), A0, A10, A01, A20, A11, A02=coefficients of the 3D regression model; equation for 3D regression model: 
y=A0+A10*x1+A01*x2+A20*x12+A11*x1*x2+A02*x22+e. 
 
 
Constraints y x1 x2 n R2adj PANOVA A0 A10 A01 A20 A11 A02 
Malignancy FH50 Fibrinogen level WBC 20 0.65 1.8x10-4 - - - 6.7x10-2 -0.46 0.87
None FD50 Fibrinogen level 
Patient 
age 100 0.37 2.2x10-9 2.7 -6.8x10-2 - 5.2x10-4 -1.2x10-3 - 
 
 
Figure VIII. The joint impact of fibrinogen level and patients’ age on the ratio of fibrin/extracellular DNA (FD50) in arterial 
thrombi. The regression model and its coefficients are presented in Table III. Regression surface is shown for data points (o)after 
outlier (x) rejection (2 outliers are not shown because they are out of the chosen ordinate scale). 
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